STOCK TITAN

NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NEXGEL (NASDAQ:NXGL) rescheduled its shareholder update conference call to April 15, 2026 at 4:30 P.M. ET to provide an update on the proposed Celularity transaction. The company said there is no assurance the transaction will close and it will not use the previously announced Securities Purchase Agreement financing.

The company is negotiating a new financing structure with a different group of investors and expects to provide additional transaction details on the April 15 call. Call and webcast access information has been provided for shareholders.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • None.

Negative

  • None.

News Market Reaction – NXGL

-2.74%
6 alerts
-2.74% News Effect
+3.7% Peak Tracked
-8.7% Trough Tracked
-$163K Valuation Impact
$5.77M Market Cap
0.2x Rel. Volume

On the day this news was published, NXGL declined 2.74%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.7% during that session. Argus tracked a trough of -8.7% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $163K from the company's valuation, bringing the market cap to $5.77M at that time.

Data tracked by StockTitan Argus on the day of publication.

LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 15, 2026, at 4:30 P.M. ET.

While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a different group of investors under a new financing structure. The Company anticipates providing additional details regarding this proposed transaction with Celularity Inc. on April 15th.

Shareholder Update Conference Call Details:
Date: April 15, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations

About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “attempt,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com


FAQ

When is NEXGEL (NXGL) holding the rescheduled shareholder update call about Celularity?

The call is scheduled for April 15, 2026 at 4:30 P.M. ET. According to the company, the call will provide additional details on the proposed transaction with Celularity and the new financing discussions.

Will NEXGEL (NXGL) use the previously announced Securities Purchase Agreement to finance the Celularity deal?

No, NEXGEL said it will not finance the transaction under the previously announced Securities Purchase Agreement. According to the company, it is negotiating a new financing structure with a different group of investors.

Has NEXGEL (NXGL) confirmed the Celularity transaction will close?

No, there is no assurance the Celularity transaction will close. According to the company, it is continuing negotiations and will provide further updates on April 15, 2026.

How can shareholders join NEXGEL's (NXGL) April 15 conference call on the Celularity transaction?

Shareholders can join by calling 1-800-267-6316 (U.S. toll free) or 1-203-518-9783 (international), or via webcast. According to the company, webcast details are available on its Events and Presentations page.

What financing changes did NEXGEL (NXGL) announce regarding the Celularity transaction?

NEXGEL announced it will seek a new financing structure with a different investor group instead of the prior Securities Purchase Agreement. According to the company, negotiations with the new group are ongoing.

What should investors expect from NEXGEL's (NXGL) April 15 update on the Celularity deal?

Investors should expect additional details about the proposed transaction and the new financing structure. According to the company, the April 15 call will outline current negotiating status and next steps, if any.